Qlife receives order from Statens Serum Institut for COVID-19 testing
Qlife announces today that Denmark’s infectious disease agency, Statens Serum Institut, has placed an order of 50 Egoo.Health devices and associated SARS-CoV-2 test capsules. The order represents a value of approximately 1 MDKK, and Qlife expects to complete the delivery in February 2021.
“It is of great importance for Qlife to get a significant order from a highly professional customer directly after the CE-marking. It manifests the demand for tests of laboratory quality combined with fast results, which is exactly what the Egoo test delivers. The Egoo.Health platform is optimal for usage in locations with limited access to central lab facilities, it is easy to use and delivers test results immediately electronically. We are proud to initiate the commercialization journey of the Egoo.health platform, as it will be a unique tool in the current fight against the pandemic”, says Jakob Broberg Lind, Director of Sales at Qlife.
The test can provide rapid detection of the current pandemic coronavirus SARS-CoV-2 in 30 minutes with less than a minute of hands on time to prepare the sample.
Egoo's SARS-CoV-2 can be utilized in multiple settings where actionable test results are needed to make informed treatment decisions quickly. The test delivers near-patient results with the same level of performance seen in reference labs.
For more information please contact:
Thomas Warthoe, CEO
+45 21 63 35 34
Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: email@example.com).Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.
This information is insider information that Qlife Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on January 29, 2021.